TUCSON, Ariz., Jan. 9, 2025 /PRNewswire/ — SynCardia Systems, LLC (“SynCardia”, or the “Company”), a Picard Medical, Inc. company, and the global leader in total artificial heart technology, is pleased to announce that the China National Intellectual Property Administration (“CNIPA”) has notified the Company of the administration’s decision to grant SynCardia its first patent covering the Company’s next-generation total artificial heart. This patent describes novel technology aimed at eliminating external drive mechanisms by fully integrating the pumping mechanism within the implanted artificial heart ventricle.

This milestone represents a significant step toward realizing SynCardia’s vision of a fully implantable total artificial heart (“Emperor”), providing a life-saving solution to patients suffering from advanced heart failure worldwide. The next-generation Emperor artificial heart design builds upon SynCardia’s proven total artificial heart technology, with innovations aimed at improving patient outcomes and expanding accessibility to life-saving cardiac support.

“We are thrilled to receive this notification from CNIPA, as it reaffirms the global impact of our mission to advance our artificial heart technology,” said Patrick NJ Schnegelsberg, CEO of SynCardia Systems. “This patent is a crucial component of our strategy to bring the SynCardia Total Artificial Heart and the next generation Emperor artificial heart to patients in China.”

SynCardia remains committed to pioneering advancements in its artificial heart technology and expanding its reach to new markets. The Company continues to work closely with international regulatory bodies and partners to ensure the future availability of its current and next-generation total artificial heart to patients worldwide.

About SynCardia Systems, LLC

SynCardia Systems, LLC is a leader in the development of total artificial hearts. The Company markets and sells the SynCardia Total Artificial Heart (“STAH”), which is the only U.S. Food and Drug Administration and Health Canada approved artificial heart[1]. The STAH has been used by over 2,100 patients worldwide.

Forward Looking Statements

This press release contains statements that are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts and can generally be identified by the use of future dates or words such as “aim,” “vision,” “strategy,” “remain,” “or “continue” or the negative of such terms and other comparable terminology. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, risks, and uncertainties that could cause actual results to differ materially from such estimates or forecasts. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information in this press release. Such forward-looking statements speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this press release except as required by law. Forward-looking statements in this press release may include, for example, statements about:  the patent’s ability to eliminate external drive mechanisms by fully integrating the pumping mechanism within the implanted artificial heart ventricle, the vision of a fully implantable total artificial heart, improving patient outcomes and expanding accessibility to life-saving cardiac support, our strategy to bring the SynCardia Total Artificial Heart and the next generation Emperor artificial heart to patients in China and our continued work with international regulatory bodies and partners to ensure the future availability of its current and next-generation total artificial heart to patients worldwide.

For media inquiries or further information, please contact the SynCardia Marketing Department via email marketing@syncardia.com.

Media Contact:
Marketing Department
Marketing@syncardia.com
520-545-1234

The SynCardia temporary Total Artificial Heart (the TAH-t) is indicated for use as a bridge to transplantation in cardiac transplant-eligible candidates at risk of imminent death from biventricular failure.

View original content:https://www.prnewswire.com/news-releases/syncardia-systems-receives-decision-to-grant-first-patent-in-china-for-the-emperor-next-generation-total-artificial-heart-302347516.html

SOURCE SynCardia Systems, LLC

LOS ANGELES, Jan. 9, 2025 /PRNewswire/ — In response to the widespread fires currently devastating Los Angeles and surrounding areas, eNavvi today announced it will provide unlimited prescription credits to physicians across the state of California. This initiative is aimed at reducing logistical barriers to essential medications during an active emergency, enabling healthcare professionals to quickly prescribe and route medications to patients in need. 

“eNavvi is designed for emergency responsiveness. We strongly believe that access to prescriptions and medications should never be an issue when dealing with far more important matters.” 
— Dr. Simon Chang, CEO, eNavvi 

Keeping Healthcare Accessible in Times of Crisis 

With wildfires severely impacting local infrastructure and preventing many patients from accessing their usual pharmacy or medical facilities, eNavvi is stepping in to fill a critical gap. The company’s proprietary digital platform allows providers to submit prescriptions and refills from any location, ensuring consistent medication access for patients during this emergency. By offering unlimited credits for prescription routing, eNavvi removes usage constraints so physicians can focus on patient care. 

Key features of eNavvi’s emergency support initiative include: 

Unlimited Prescription Credits for Providers: All California physicians have unrestricted access to eNavvi’s prescribing platform at no additional cost.Statewide Availability: Physicians and patients across California can access the program, ensuring consistent and reliable medication delivery.Streamlined Digital Platform: eNavvi’s user-friendly interface allows physicians and patients to manage prescriptions from the safety of their homes or temporary shelters.

“Our goal is to ensure that healthcare access is never compromised,” said Dr. Reddy Pathakota, CFO, eNavvi. “We are proud to stand shoulder-to-shoulder with the brave first responders, physicians, and volunteers who are on the ground, putting their lives at risk for the safety of our communities.” 

How to Utilize Unlimited Prescription Credits 

Physicians Enroll with eNavvi: Register or log in to the eNavvi portal to confirm unlimited credit status. Submit Prescriptions as Needed: Providers can route an unlimited number of prescriptions and refills for patients in affected areas. Delivery or Pickup Options: Once routed, prescriptions may be delivered via mail-order (where available) or picked up at a partnering pharmacy.

Physicians or patients seeking immediate assistance can reach out to eNavvi’s email contact@enavvi.com for guidance. 

About eNavvi 

eNavvi is a leading digital healthcare platform focused on delivering efficient, affordable, and accessible prescriptions to patients nationwide. By leveraging advanced technology and strategic partnerships, eNavvi streamlines the pharmacy experience and empowers individuals to take control of their health. Whether during routine care or the midst of a crisis, eNavvi aims to reduce barriers to essential medications and provide critical support to communities in need. 

For more information, please visit www.enavvi.com. 

View original content to download multimedia:https://www.prnewswire.com/news-releases/amid-california-wildfires-enavvi-mobilizes-unlimited-prescription-credits-for-healthcare-providers-302347522.html

SOURCE eNavvi

BELLEVUE, Wash., Jan. 9, 2025 /PRNewswire/ — Belva AI today unveils Belva Engineer, a groundbreaking AI-powered development and workflow platform designed to elevate software development. By integrating AI-driven automation with innovative features like blueprint-driven development, Belva Engineer empowers engineers, developers, and technology leaders to reimagine how software is built, deployed, and maintained.

Belva Engineer combines two core offerings—Developer and Architect seats—tailored to meet the needs of diverse user groups, from independent developers to enterprise DevOps teams and CTOs. With cutting-edge tools like automated hosting, full-context AI code generation, and AI-generated diagrams, the platform eliminates inefficiencies, allowing users to focus on creativity and strategic software design.

“Belva Engineer is a paradigm shift for developers,” said Michael Uvalle, CEO at Belva AI. “By automating the mundane and streamlining the complex, we’re empowering engineers to focus on innovation and strategic decision-making, fundamentally transforming the way software is built.”

Key Features and Benefits

Architect Seat

AI-Generated Diagrams: Use conversational inputs to generate actionable blueprints for new or existing projects. These diagrams drive superior AI-generated code quality and align with project architecture.Blueprint-Driven Development: Simplify complex system development, ensure accurate updates, and streamline legacy maintenance.Enhanced AiDB Technology: Map and index codebases to enable precise, context-aware code creation and modifications.

Developer Seat

AI Code Generation: Create high-quality, executable code directly from natural language inputs, accelerating development and minimizing errors.Automated Hosting: Simplify deployment with server environment configurations tailored for monolith architectures.AiDB Technology: Eliminate context limitations for large language models (LLMs), enabling full-context understanding of entire codebases.

By combining these features, Belva Engineer introduces a complete, cohesive environment that eliminates the need to juggle disparate tools, enabling developers to work smarter and faster.

Addressing Market Needs

The demand for low-code and generative AI solutions is skyrocketing, with no-code technologies projected to power 70% of new business applications by the end of 2025. Belva Engineer’s comprehensive offering meets this demand while addressing critical developer needs, including security, scalability, and explainable AI outputs.

“Our vision is to help developers evolve into architects, where they can design and manage software with increased clarity and precision,” added Uvalle. “With Belva Engineer, we’re delivering tools that inspire innovation while maintaining the integrity and structure of complex projects.”

Availability

Belva Engineer is available starting January 9, 2025. Users can sign up and explore its transformative features at belva.ai/belva-engineer-signup.

About Belva AI

Belva AI is a leader in AI-driven technologies that empower developers and teams to build software with simplicity, transparency, and precision. Through innovative tools like Belva Engineer, the company aims to redefine how software is created in the age of AI.

Media Contact

For more information or to schedule an interview with Belva AI’s leadership, please contact Thad Lewis at thad@belva.ai.

View original content to download multimedia:https://www.prnewswire.com/news-releases/belva-engineer-transforms-software-development-with-ai-powered-all-in-one-workflow-environment-302347366.html

SOURCE Belva AI